Soleno Therapeutics/$SLNO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Soleno Therapeutics
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
Ticker
$SLNO
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
115
Website
SLNO Metrics
BasicAdvanced
$4.5B
-
-$4.65
-2.67
-
Price and volume
Market cap
$4.5B
Beta
-2.67
52-week high
$90.32
52-week low
$41.50
Average daily volume
1.4M
Financial strength
Current ratio
19.637
Quick ratio
18.432
Long term debt to equity
22.473
Total debt to equity
22.73
Interest coverage (TTM)
-128.22%
Profitability
EBITDA (TTM)
-202.13
Management effectiveness
Return on assets (TTM)
-52.40%
Return on equity (TTM)
-105.54%
Valuation
Price to book
17.81
Price to tangible book (TTM)
18.31
Price to free cash flow (TTM)
-40.628
Free cash flow yield (TTM)
-2.46%
Free cash flow per share (TTM)
-2.098
Growth
Earnings per share change (TTM)
106.82%
3-year earnings per share growth (CAGR)
-3.69%
10-year earnings per share growth (CAGR)
-38.77%
Bulls say / Bears say
FDA approval of VYKAT XR for treating hyperphagia in Prader-Willi syndrome positions Soleno Therapeutics as a leader in this niche market, potentially driving significant revenue growth. (globenewswire.com)
The European Medicines Agency's validation of the Marketing Authorization Application for DCCR tablets indicates potential expansion into European markets, broadening the company's revenue base. (globenewswire.com)
Analyst upgrades and increased institutional investment reflect growing confidence in Soleno's strategic direction and product pipeline. (etfdailynews.com)
The Phase 3 DESTINY PWS trial failed to achieve statistical significance on the primary hyperphagia endpoint, raising concerns about the robustness of efficacy data. (panabee.com)
Soleno reported a $176 million net loss in 2024, with an accumulated deficit of $452 million, indicating financial instability. (panabee.com)
The FDA extended the review period for DCCR to March 27, 2025, suggesting potential regulatory hurdles and delaying potential revenue. (panabee.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Soleno Therapeutics stock?
Soleno Therapeutics (SLNO) has a market cap of $4.5B as of July 29, 2025.
What is the P/E ratio for Soleno Therapeutics stock?
The price to earnings (P/E) ratio for Soleno Therapeutics (SLNO) stock is 0 as of July 29, 2025.
Does Soleno Therapeutics stock pay dividends?
No, Soleno Therapeutics (SLNO) stock does not pay dividends to its shareholders as of July 29, 2025.
When is the next Soleno Therapeutics dividend payment date?
Soleno Therapeutics (SLNO) stock does not pay dividends to its shareholders.
What is the beta indicator for Soleno Therapeutics?
Soleno Therapeutics (SLNO) has a beta rating of -2.67. This means that it has an inverse relation to market volatility.